A randomized trial of edivoxetine in pediatric patients with attention-deficit/hyperactivity disorder

Journal of Child and Adolescent Psychopharmacology

Volumn 24, Issue 4, 2014, Pages 190-200

  Lin, Daniel Y ^a   Kratochvil, Christopher J ^b   Xu, Wen ^a   Jin, Ling ^a   D'Souza, Deborah N ^c   Kielbasa, William ^a   Allen, Albert J ^a  

^a ELI LILLY AND COMPANY   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c SYNEOS HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; EDIVOXETINE; METHYLPHENIDATE; OSMOTIC RELEASE ORAL SYSTEM METHYLPHENIDATE; PLACEBO; UNCLASSIFIED DRUG; ADRENERGIC RECEPTOR AFFECTING AGENT; ALPHA-((5-FLUORO-2-METHOXYPHENYL)METHYL)-ALPHA-(TETRAHYDRO-2H-PYRAN-4-YL)-2-MORPHOLINEMETHANOL; CENTRAL STIMULANT AGENT; MORPHOLINE DERIVATIVE; PHENETHYL ALCOHOL;

ADOLESCENT; AGGRESSION; ARTICLE; ATTENTION DEFICIT DISORDER; ATTENTION DEFICIT DISORDER RATING SCALE; BEHAVIOR DISORDER; BODY WEIGHT DISORDER; CHILD; CLINICAL GLOBAL IMPRESSION SCALE; CONDUCT DISORDER; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DEPRESSION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EFFECT SIZE; EMOTIONAL DISORDER; FATIGUE; FEMALE; GASTROENTERITIS; GENERALIZED ANXIETY DISORDER; HEART ARRHYTHMIA; HEART RATE; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MANIA; MOOD CHANGE; MULTICENTER STUDY; NAUSEA; OROPHARYNX PAIN; OUTCOME ASSESSMENT; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECOMMENDED DRUG DOSE; SEDATION; SEPARATION ANXIETY; SIDE EFFECT; SLEEP DISORDER; SOCIAL PHOBIA; SOMNOLENCE; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; VOMITING; ANALOGS AND DERIVATIVES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; PSYCHOLOGICAL RATING SCALE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHYLPHENIDATE; MORPHOLINES; PHENYLETHYL ALCOHOL; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84901248224     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2013.0043     Document Type: Article

References (23)

1. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision. Washington, DC: American Psychiatric Association; 2000
2. Conners CK: Conners Rating Scales-Revised. North Tonawanda, New York: Multi-Health Systems, Inc.; 1997
3. Culpepper L: Primary care treatment of attention-deficit/hyperactivity disorder. J Clin Psychiatry 67 Suppl 8:51-58, 2006
4. Del Campo N, Chamberlain SR, Sahakian BJ, Robbins TW: The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol Psychiatry 69:e145-e157, 2011
5. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R: ADHD Rating Scale-IV: Checklists, norms, and clinical interpretations. New York, Guilford Press, 1998
6. Faries DE, Yalcin I, Harder D, Heiligenstein JH: Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Atten Disord 5:107-115, 2001
7. Grizenko N, Lachance M, Collard V, Lageix P, Baron C, Ben Amor L, Stepanian MT, Mbekou V, Schwartz G, Bellingham J, Joober R: Sensitivity of tests to assess improvement in ADHD symptomatology. Can Child Adolesc Psychiatr Rev 13:36-39, 2004
8. Grizenko N, Rodrigues Pereira RM, Joober R: Sensitivity of scales to evaluate change in symptomatology with psychostimulants in different ADHD subtypes. J Can Acad Child Adolesc Psychiatry 22:153-158, 2013
9. Guy W: ECDEU assessment manual for psychopharmacology, Revised. Rockville, MD: United States Department of Health, Education, and Welfare; 1976
10. Hazell P: Review of attention-deficit/hyperactivity disorder comorbid with oppositional defiant disorder. Australas Psychiatry 18:556-559, 2010
11. Jin L, Xu W, Krefetz D, Gruener D, Kielbasa W, Tauscher-Wisniewski S, Allen AJ: Clinical outcomes from an open-label study of edivoxetine in pediatric patients with attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol 23:200-207, 2013
12. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N: Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980-988, 1997
13. Kielbasa W, Quinlan T, Jin L, Xu W, Lachno DR, Dean RA, Allen AJ: Pharmacokinetics and pharmacodynamics of edivoxetine (LY2216684), a norepinephrine reuptake inhibitor, in pediatric patients with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 22:269-276, 2012
14. Matza LS, Rentz AM, Secnik K, Swensen AR, Revicki DA, Michelson D, Spencer T, Newcorn JH, Kratochvil CJ: The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder. J Dev Behav Pediatr 25:166-174, 2004
15. Michelson D, Allen AJ, Busner J, Casat C, Dunn D, Kratochvil C, Newcorn J, Sallee FR, Sangal RB, Saylor K, West S, Kelsey D, Wernicke J, Trapp NJ, Harder D: Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. Am J Psychiatry 159:1896-1901, 2002
16. Michelson D, Faries D, Wernicke J, Kelsey D, Kendrick K, Sallee FR, Spencer T; Atomoxetine ADHD Study Group: Atomoxetine in the treatment of children and adolescents with attention-deficit/ hyperactivity disorder: A randomized, placebo-controlled, doseresponse study. Pediatrics 108:E83, 2001
17. Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, Michelson D: Atomoxetine/Methylphenidate Comparative Study Group: Atomoxetine and osmotically releasedmethylphenidate for the treatment of attention deficit hyperactivity disorder: Acute comparison and differential response. Am J Psychiatry 165:721-730, 2008
18. National High Blood Pressure Education Program Working Group (NHBPEPWG) on High Blood Pressure in Children and Adolescents: The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents. Pediatrics 114 Suppl 2:555-576, 2004
19. Pliszka SR: Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: An overview. J Clin Psychiatry 59 Suppl 7:50-58, 1998
20. Posner K, Oquendo MA, Gould M, Stanley B, Davies M: Columbia Classification Algorithm of Suicide Assessment (C-CASA): Classification of suicidal events in the FDA's pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 164:1035-1043, 2007
21. Quintero J, López-Munöz F, Alamo C, Loro M, García-Campos N: Reboxetine for ADHD in children non-responders or with poor tolerance to methylphenidate: A prospective long-Term open-label study. Atten Defic Hyperact Disord 2:107-113, 2010
22. Swanson JM: School-based assessments and interventions for ADD students. Irvine, CA: K.C. Publishing, 1992
23. Wilens TE: Mechanism of action of agents used in attention-deficit/ hyperactivity disorder. J Clin Psychiatry 67 Suppl 8:32-38, 2006